Deals this week: Siemens Healthineers, Fresenius SE & Co, Psoria-Shield

19 January 2017 (Last Updated January 19th, 2017 18:30)

Siemens Healthineers and Biogen have signed an agreement to jointly develop new magnetic resonance imaging (MRI) tools for multiple sclerosis (MS). The agreement aims to quantify key markers of multiple sclerosis disease activity and progression.

Siemens Healthineers and Biogen have signed an agreement to jointly develop new magnetic resonance imaging (MRI) tools for multiple sclerosis (MS). The agreement aims to quantify key markers of multiple sclerosis disease activity and progression.

The collaboration enables the development of a solution that can be integrated into the existing radiology workflow and provides high-quality, standardised data to the neurologists resulting in more informed treatment decisions and improved patient outcomes.

German health care company, Fresenius SE & Co, intends to raise gross proceeds of €700m ($742.54m) through a private placement of 0.875% unsecured notes due 2022.

"The amount raised from the offerings will be used by the company for the acquisition of Quironsalud and for other general corporate purposes."

Concurrently, it has also completed the private placement of 1.5% unsecured note due 2024 to raise gross proceeds of €700m ($742.54m), 2.125% unsecured note due 2027 for gross proceeds of €700m ($742.54m), and 3% unsecured note due 2032 for gross proceeds of €500m ($530.4m).

The amount raised from the offerings will be used by the company for the acquisition of Quironsalud and for other general corporate purposes.

Medical device company, Psoria-Shield, has granted non-exclusive rights to NewSurg, a medical lasers and equipment developer, for the commercialisation of its Psoria-Light (PL 1000) system in the US.

Pursuant to the agreement, NewSurg will buy a minimum of two Psoria-Light systems, which are phototherapy devices used to target skin conditions, and place them with dermatologists, who are seeking an alternative treatment to replace their existing aging and costly excimer phototherapy lasers.

Psoria-Shield intends to expand its domestic reach by marketing the product through NewSurg’s sales and marketing channels.

Oncology-related precision diagnostics developer, Cancer Genetics (CGI), has partnered with biotech company, Lantern Pharma, for drug rescue & repurposing using genomics, biomarkers and artificial intelligence-driven development for the latter’s lead clinical-stage drug candidates.

The collaboration will build on CGI’s biomarker discovery, clinical trial testing, and companion diagnostic development capabilities coupled with Lantern’s artificial intelligence and big-data driven development approach.